Aminocaproic Acid

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Inhibits
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Hungary: Acepramin; Poland: Acidum e-aminocapr.; Portugal: Epsicaprom; Spain: Caproamin.

North America

USA: Amicar, Aminocaproic, Aminocaproic Acid.

Latin America

Argentina: Caprocat, Ipsilon; Brazil: Ipsilon.

Drug combinations


Aminocaproic Acid: C~6~H~13~NO~2~. Mw: 131.17. 6-Aminohexanoic acid. CAS-60-32-2 (1963).

Pharmacologic Category

Antihemorrhagic Agents; Hemostatics. (ATC-Code: B02AA01).

Mechanism of action

Binds to and blocks the activation of plasminogen (PLAT), thus inhibiting the subsequent conversion of fibrin to plasmin (fibrinolysis).

Therapeutic use

To enhance hemostasis of excessive bleeding from fibrinolysis (causes may include cardiac surgery, hematologic disorders, neoplastic disorders, abruption placentae, hepatic cirrhosis and urinary fibrinolysis).

Pregnancy and lactiation implications

Use caution if administered during pregnancy or lactation.

Unlabeled use

Treatment of traumatic hyphema. Control bleeding in thrombocytopenia and in oral bleeding in coagulation disorders. Topical treatment of bleeding associated with dental procedures in patients on oral anticoagulant therapy. Prevention of perioperative bleeding associated with cardiac surgery.


Disseminated intravascular coagulation (without heparin). Active intravascular clotting process.

Warnings and precautions

Intrarenal obstruction may occur secondary to glomerular capillary thrombosis or clots in the renal pelvis and ureters (do not use in hematuria of upper urinary tract origin unless possible benefits outweigh risks). Skeletal muscle weakness has been reported with prolonged use. Caution in renal impairment (may accumulate). Do not administer with factor IX complex concentrates or anti-inhibitor coagulant complexes (risk of thrombosis). Injection contains benzyl alcohol («gasping syndrome» in neonates). Rapid I.V. administration should be avoided.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart